Male Enhancement Raw Steroid Powder Cialis / Tadalafil CAS 171596-29-5

Item	Standard	Result
Appearance	White crystalline powder	complies
Melting Point	300ºC ~303ºC	301.5ºC-302.5ºC
Loss on drying	NMT 0.5%	0.23%
Heavy metals(Pb)	NMT 20ppm	6.0ppm
Residue on ignition	NMT 0.1%	0.08%
Relative substance	NMT 1.0%	0.17%
Assay (on dried basis)	NLT 98.5%	99.67%
Conclusion	Conforms with standard USP36

 

 

Abstract

 

Tadalafil (Tadalifil citrate), a phosphodiesterase type 5 inhibitor, is used to treat erectile dysfunction (ED) and decreased libido in males. Tadalafil works by aiding relaxation of blood vessels and increasing blood flow in the penis during sexual arousal, resulting in improved erectile function. Tadalafil is much longer lasting. Effects can be felt anywhere between 36-48 hours.

 

What does tadalafil do for a man?

 

Tadalafil is a medication primarily used to treat erectile dysfunction (ED) in men. It belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. When a man experiences ED, it means he has difficulty achieving or maintaining an erection sufficient for sexual activity.

Tadalafil works by inhibiting the action of the PDE5 enzyme, which is responsible for breaking down a chemical called cyclic guanosine monophosphate (cGMP). Normally, cGMP helps relax the blood vessels in the penis, allowing an increased blood flow into the erectile tissues during sexual stimulation. This increased blood flow leads to an erection.

By blocking PDE5, tadalafil helps to preserve higher levels of cGMP, which in turn enhances the relaxation of blood vessels and increases blood flow to the penis. As a result, men who take tadalafil can experience improved erectile function and maintain erections sufficient for sexual activity.

What is the development background of Cialis?

Cialis (Tadalafil) is a medication used primarily to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Its development is a result of years of research aimed at improving the treatment of ED, a condition affecting millions of men worldwide. The following is an overview of its development background:

Early Development and Discovery:

Origin of Tadalafil:

Tadalafil, the active ingredient in Cialis, was discovered by researchers at ICOS Corporation, a biotechnology company based in Bothell, Washington. The company was focused on developing drugs that could help with erectile dysfunction.

In the late 1980s and early 1990s, research into improving treatments for ED was in full swing. ICOS scientists were particularly interested in the enzyme phosphodiesterase type 5 (PDE5), which plays a key role in regulating blood flow in the penis. PDE5 inhibitors were seen as potential treatments for ED by allowing more blood flow into the penis during sexual stimulation.

Tadalafil's Mechanism:

Tadalafil is a PDE5 inhibitor, meaning it works by blocking the action of the PDE5 enzyme. By inhibiting PDE5, tadalafil helps to relax the blood vessels in the penis, enhancing the effect of nitric oxide, which is released during sexual arousal. This increased blood flow leads to an erection.

Tadalafil's long-lasting effects-up to 36 hours-made it distinct from other ED drugs, such as sildenafil (Viagra), which had a shorter duration of action (around 4-6 hours). This long duration earned Cialis the nickname "the weekend pill".

Collaboration with Eli Lilly:

Partnership with Eli Lilly:

ICOS Corporation entered into a partnership with Eli Lilly and Company, one of the largest pharmaceutical companies in the world, to further develop and market tadalafil. The collaboration leveraged Eli Lilly's resources and global reach to bring Cialis to the market.

Eli Lilly took over the commercialization and distribution of Cialis, while ICOS continued with the drug's research and development.

Clinical Trials and Approval:

Clinical Trials:

Extensive clinical trials were conducted to evaluate the safety and efficacy of tadalafil for treating erectile dysfunction. These trials demonstrated that tadalafil was not only effective at improving erectile function but also had a significantly longer duration of action compared to other PDE5 inhibitors like sildenafil (Viagra).

Tadalafil also showed promise in treating benign prostatic hyperplasia (BPH), a condition commonly associated with aging men, where the prostate becomes enlarged and causes urinary problems. This led to further clinical trials investigating its dual use for both ED and BPH.

FDA Approval:

In 2003, the U.S. Food and Drug Administration (FDA) approved Cialis for the treatment of erectile dysfunction (ED). The approval was based on the results of clinical trials showing that tadalafil was both safe and effective for men suffering from ED.

In 2008, the FDA approved a lower daily dose of Cialis (2.5 mg and 5 mg) for men who wished to take the medication daily, as opposed to the on-demand use of the 10 mg and 20 mg doses. This option was aimed at providing more flexibility for men who wanted to engage in sexual activity without having to plan ahead.

Approval for BPH:

In 2011, the FDA also approved Cialis for the treatment of benign prostatic hyperplasia (BPH), further expanding the drug's therapeutic use. Clinical studies showed that tadalafil could effectively relieve the symptoms of BPH, such as difficulty urinating and frequent urination.

Market Success:

Widespread Use:

Cialis became one of the most prescribed medications for erectile dysfunction due to its long-lasting effects and flexible dosing options. The fact that it can remain effective for up to 36 hours made it a preferred choice for many men who sought a more spontaneous sexual experience.

Cialis's approval for BPH further boosted its popularity, as it provided a solution for two common male health issues in one pill.

Competition and Generic Versions:

Sildenafil (Viagra) from Pfizer was the first PDE5 inhibitor to be approved for ED and remained Cialis's primary competitor for many years. However, Cialis gained popularity due to its longer duration of action.

In 2018, generic tadalafil was approved, making the medication more accessible and affordable. However, Cialis remains a well-known brand name, with Eli Lilly continuing to market it globally.

Conclusion:

Cialis (tadalafil) was developed through a combination of targeted research on PDE5 inhibitors and a collaboration between ICOS Corporation and Eli Lilly. It revolutionized the treatment of erectile dysfunction due to its long duration of action, and its approval for the treatment of benign prostatic hyperplasia further expanded its therapeutic applications. Cialis remains one of the most commonly prescribed medications for both ED and BPH, and its development marked an important milestone in the treatment of male sexual health issues.

 

Steroid Hormone Powder